retatrutide triple agonist glp-1 gip glucagon Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Retatrutide 10mg — Triple Receptor
Description
Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a novel and effective solution, having initially been approved and marketed for glycemic control in type 2 diabetes
Nat Cell Biol 2:805811
Each mechanism attacks a different piece of the belly fat puzzle
Full data will be presented at the 2026 American Diabetes Association annual meeting
Studies comparing patients who maintained strict diet and exercise versus those who discontinued medication show that biological factors dominate outcomes
01053-X/asset/826330f0-5581-4d6d-8f45-2192fe6ac242/main.assets/gr2_lrg.jpg)
Did You Know: The discontinuation rate due to side effects at the 12mg dose was only 11.2% in trials
